| .
Scientifically, how could this possibly be true? How could molecules extracted from mundane vegetal sources have a profound influence on the brain? A Completely Safe, Non-Drug,
Natural Approach Flavay® is totally safe to use; a 100% non-toxic and natural—but powerfully effective—nutritional supplement. Flavay® is a highly specialized, nutritional complex of pairs and triples of a specific molecule called "flavan-3-ol," isolated from natural extracts, that has been extensively tested and examined clinically for biological antioxidant protection, collagen strengthening, tissue rebuilding, and other health producing outcomes. Manufactured and used in France since 1950 for circulatory problems, inflammation and allergies, a more recent use of Flavay® has arisen among people suffering from a lack of concentration and attention. It is said to have begun quite accidentally when people took the product for another purpose, such as allergies, and noticed an improvement in concentration and mental focus—the classic symptoms of attention deficit. Scientifically, how could this possibly be true? How could molecules extracted from mundane vegetal sources have a profound influence on the brain? According to scientific research, there are a number of mechanisms of action. Many decades of studies have established that Flavay® improves circulation, including microcirculation in the brain. Flavay® is one of the few dietary antioxidants that readily crosses the blood-brain barrier to protect brain cells. The blood-brain barrier protects the brain from compounds that normally circulate in the blood. Brain cells are very sensitive to some compounds, even though they may not damage other cells in the body or even be needed by other cells. In laboratory experiments in which blood is rapidly injected into brain blood vessels, dramatically increasing the blood pressure within those vessels for a brief time, Flavay® shows a significant protective effect. (3, 4, 1)
There is also evidence that Flavay® may help the body to regulate enzymes which control the crucial neurotransmitters dopamine and norepinephrine, chemicals that carry messages among brain cells and are involved in excitatory responses. Flavay’s® ability to support healthy blood flow to the brain is also important to brain function. Researchers have shown that decreased blood flow to the brain plays a major role in age-related brain disorders. Flavay® may also help deliver other nutrients to the brain, such as zinc and selenium, which are essential to normal brain function, according to recent research. Preliminary studies have confirmed what many users of this remarkable complex have experienced: striking benefits in improved concentration and mental focus, the classic symptoms of attention deficit disorder. (115, 3, 4) A preliminary study by a psychologist in Tulsa, Oklahoma, who specializes in treating attention deficit disorder, found striking benefits from these naturally-derived molecules, known as Flavay®. The researchers found that it worked just as well as the commonly prescribed stimulant medications, including Ritalin, on thirty children and adults diagnosed with ADD. The subjects were given a battery of computerized and behavior tests to judge their attention, concentration, and other important factors in ADD under various circumstances: when they were either on or off their usual stimulant medications, or on Flavay® alone. When they were off their medications, their ADD deteriorated. On their medications, they were much improved. But when they took daily doses of Flavay®, their scores and behavior were just as improved as when they took stimulant drugs. Many of the subjects also had other positive effects. (115)
This nontoxic, water soluble nutrient holds promise as an alternative to Ritalin. Many children with ADD have found this substance effective to decrease their symptoms by normalizing brain function. It seems to improve memory by improving circulation to the brain. Free radicals reprogram DNA and have been implicated in more than sixty diseases. Flavay® has been shown to help in inflammation of the joints and other tissues, as well as improve functioning of the circulatory, nervous and immune systems. (131, 1) Flavay® Supports The Brain-Immune Connection
Top research institutions worldwide now understand that there is a two-way chemical dialog between the brain and the immune system. Each can influence the other directly. There is an ongoing chemical dialog between the brain and the immune system, a connection that depends on two languages: the neurotransmitters of the brain, and the immunotransmitters of the immune system. (2) Flavay® supports your immune system in several important ways. First, by recycling the activity of vitamins C and E—key players in the body's immune system—Flavay® gives the body more ammunition to fight infection. Second, research demonstrates that Flavay® prevents free radical damage to macrophages, a type of white blood cell that generates nitric oxide to destroy bacteria, viruses, and host parasites. (4, 5, 2) As long as nitric oxide is produced in the right amount, it is
beneficial to the body; nitric oxide fights infection, kills tumor
cells, and promotes wound healing. But when nitric oxide is produced
in excess, it throws the brain-immune connection off kilter and
causes some of the brain's worst free radical damage. Over the
past decade, scientists have shown that the production of nitric
oxide through the combination of immune and nervous system activity
(often sparked by an infection, exposure to a toxin, or as part
of the aging process) plays a key role in the development of neurological
diseases. Thus, Flavay’s® ability to help regulate nitric
oxide can profoundly benefit the body’s immune and brain
functions. (2) Flavay Plus®
Adds Synergistic Help
Flavay Plus® uses a synergistic blend of Flavay® with antioxidant vitamins, minerals and other phytonutrients to best take advantage of the dynamic interplay among the key antioxidants and their co-factor nutrients. Phosphatidyl serine: Flavay Plus® is formulated with phosphatidyl serine (Leci-PS™), a complex of amino and fatty acids extracted from soy lecithin, which has proven to be a safe, potentially effective therapeutic agent in treating memory deficit disorders and is an often-used supplement for attention deficit disorders. Phosphatidyl serine has been the subject of many human clinical trials regarding memory loss, mood, cognitive performance, learning ability and stress. Many studies show that phosphatidyl serine can optimize cognition. In the most famous human study, researchers gave 300 mg of phosphatidyl serine a day for 12 weeks to 149 subjects over 50. Various memory and learning tests were administered before and after. The results showed that phosphatidyl serine managed to raise cognitive performance to the levels typical for as much as 12 years younger. (26, 28) In a study where a group of 27 ADHD children took 200 to 300
mg of phosphatidyl serine daily for four months, researchers found
that 25 children exhibited improvement in learning capacity and
behavior; and the researchers noted that there were no adverse
affects. Scientific studies have demonstrated that phosphatidyl serine supplementation can increase the output of acetylcholine, the neurotransmitter so important to memory. Clinical trials with elderly patients suffering from memory deficit disorders have shown that adding phosphatidyl serine to the daily diet improved the ability of these patients to think and decreased behavioral disturbances. In other studies, phosphatidyl serine also improved the performance of patients with age-associated memory impairment, a disorder affecting millions of Americans each year. (32) Flavay Plus® Provides
Synergistic Help for Coping With Stress
Research has shown that phosphatidyl serine works to keep the brain’s processes within normal limits, raising them when they are low and lowering them when they are high. So phosphatidyl serine boosts the weak stress response in the elderly person and calms down exaggerated stress in the healthy young person. Both physical and mental stressful conditions cause stress hormones to be released into circulation, even in the young and healthy. Phosphatidyl serine given to athletes prior to starting exercise produced an impressive degree of down-regulation of the stress hormones. Phosphatidyl serine may have the capacity to “normalize” the stress-induced activation of the hypothalamic-pituitary-adrenal axis. In a double-blind, placebo-controlled study conducted in Italy, phosphatidyl serine lowered stress hormone (cortisol) production by 30 percent. (31)
Two more recent placebo controlled studies confirmed the earlier double-blind trials; young, university students experienced significantly less stress from tests when they took phosphatidyl serine (300 mg daily for 30 days), they stayed more clear-headed and composed, and kept a more stable mood. (148, 149) Altogether, this research shows that Flavay Plus® can help young people confront the stressful challenges of living in today's world. Ginkgo biloba leaf: Flavay Plus® also includes standardized ginkgo biloba leaf extract, primarily known as a brain booster. In Germany and France, ginkgo biloba extract is commonly prescribed for mental problems that are often caused by poor circulation to the brain, such as difficulty concentrating, poor memory, confusion, depression, and anxiety. There have been numerous European studies conducted on ginkgo biloba extract and many have reported positive effects in terms of memory and acuity. Recently, the New York Institute for Medical Research conducted a double-blind, placebo-controlled study using ginkgo biloba extract on patients suffering from dementia (caused by either stroke or Alzheimer’s disease), with positive results. This is significant because there are few drugs that have any impact at all on cases of dementia. And, the study was published in a mainstream medical journal. (34) Vitamin A (Beta-carotene and cartenoids): Flavay Plus® contains the preferred form of Vitamin A, beta-carotene (Betatene™). Beta-carotene is converted by the body into vitamin A only as the body needs it and what isn't converted remains as a powerful antioxidant, shown to be a cancer preventative, shown to strengthen the immune system and benefit the eyes and cardiovascular system. The beta-carotene in Flavay Plus® is the highest quality, full-spectrum, patented Betatene™, a complete array of plant-derived, antioxidant cartenoids: beta-carotene, alpha-carotene, cryptoxanthin, zeaxanthin, lutein, and lycopene. (9, 6) B-Vitamins: Flavay Plus® is also formulated with many B-vitamins, which are an important requirement of the brain’s diet as they help form neurotransmitters (the chemical messengers of the nervous system). Pyridoxal phosphate, a vitamin B-6 member, is pivotal in the synthesis of the neurotransmitters serotonin, dopamine and gamma-amino butyric acid (GABA). For people who are over stimulated, GABA induces a balancing relaxation. Some people with anxiety, panic disorders, and depression may not manufacture sufficient levels of GABA. (38, 39, 40, 41, 42, 43, 44) Some nutrient deficiencies can produce symptoms that are familiar as symptoms of hyperactivity and learning disorders. A deficiency of thiamin (vitamin B-1), for example, may produce irritability, nervousness and even increased sensitivity to noise. (45) Some neurological childhood conditions appear to be connected to the B-vitamins. A study conducted at Saint Joseph Hospital in Pennsylvania found low serotonin (a neurotransmitter involved with mood) levels in hyperactive children. The researchers gave some of the subjects vitamin B-6 and observed their serotonin levels rise appreciably. Also, research suggests that a deficiency of vitamins B-2 and B-6 play a primary role in the cause of emotional disorders. (39, 43) Vitamin B-12 deficiency can mimic Alzheimer’s disease: vitamin B-12 deficiency may cause fatigue, headaches, heart and nervous system disturbances such as numbness and tingling of the arms or legs, depression, mental confusion, and memory deficits. (9) Vitamin C: Flavay Plus® also contains vitamin C: water-soluble, a potent free radical scavenger, recycles vitamin E, plays a primary role in the formation of collagen, essential for vascular health and a strong immune system. Controlled studies prove the contribution of vitamin C in the manufacture of white blood cells and interferon. (6, 7, 8, 9, 95) Flavay Plus® uses Ester-C™, a patented, revolutionary form of vitamin C that gets into the blood stream faster than ordinary vitamin C, in larger amounts with less waste, stays in the body longer, and is used more efficiently by cells and connective tissues. Ester-C™ is also buffered and stomach-friendly. It's also important to note that Flavay® dramatically extends the activity of vitamin C in the body. Vitamin E: The body’s principal fat-soluble antioxidant. Much of the body’s free radical damage occurs in fats and in fatty membranes of cells—exactly where vitamin E protects the body. (6, 7, 8, 9, 95) Selenium: Flavay Plus® includes selenium, as it is necessary for the body’s production of glutathione (an antioxidant produced by the body which protects the brain and nerve tissue from the harmful effects of free radicals) and thioredoxin reductase which recycles vitamin C. Selenium also has a synergistic effect with vitamin E, which means that the two combined are more powerful than either alone. Many Americans do not consume even the small RDA of selenium in their diet. (6, 7, 8, 9) Zinc: Flavay Plus® also includes zinc because a number of studies are pointing to an association between zinc deficiency and ADHD. One such 1996 study, published in the Journal of Child Psychology and Psychiatry, revealed a statistically significant correlation between zinc and fatty acids, in that both were decreased in children with ADHD. In another study, conducted at Ohio State University, investigators found a relationship between zinc deficiency and response to stimulant therapy among people with ADHD. Basically, this study showed that children diagnosed with ADHD may be zinc deficient, and that this deficiency may result in their poor response to stimulant therapy. (2) An essential mineral, zinc has many important effects on the brain and immune system, including neurotransmitter production and enzyme functioning. Zinc is a necessary part of the body’s production of DHA and a constituent of many vital enzymes, including superoxide dismutase (SOD), which is a critical cellular antioxidant enzyme that is responsible for mopping up peroxynitrate, the highly toxic free radical produced in abundance in the normal course of immune system battles (as in viral or bacterial infections) and plays a powerful role in immune system inflammation. Together with the B vitamins, zinc assists in the utilization of insulin and glucose. There is a growing body of evidence to indicate that zinc is needed for the proper maintenance of vitamin E levels in the blood and aids in the absorption of vitamin A. Other important functions of zinc include the promotion of glandular and reproductive health; and there is strong evidence that zinc is required for the synthesis of the nucleic acids RNA and DNA, which are essential for cell repair and cell growth. Studies have found large percentages of apparently healthy children to be deficient in zinc. There is evidence that zinc levels fall after physical and mental stress. Flavay Plus® uses zinc orotate, a high-quality, highly bioavailable form of zinc. (6, 7, 8, 9) Flavay Plus® utilizes the dynamic interplay between these nutrients and their co-factors in order to provide you and your family with the best that nutritional science has to offer in a convenient, cost effective capsule. Proven Safety of Flavay® After more than 50 years of human use, no adverse effects have been observed. Furthermore, intensive biological, toxicological, pharmacological and analytical research was conducted for the purpose of registering it as a medicine in France and other countries in Europe. In one study, daily doses of up to 35,000 mg for six months were determined to cause no adverse effects. Flavay® was also clinically tested, in particular for all sorts of symptoms related to venolymphatic insufficiencies (strenghthening veins, improving circulation and reducing edema and inflammations). The spin-off is a goldmine of data: The rigorous testing to meet the standards required by the health ministries of France, Germany and other European countries demonstrate that Flavay® is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth defects, and is completely safe. (3, 4, 109-114) Dr. Masquelier’s unequaled manufacturing process has been conducted for half a century at the very same facilities in France, and under the control of French Pharmaceutical inspection. These time-proven standards serve as a reliable assurance of the quality, consistency, bioavailability and safety of Flavay®. Who can take Flavay®? Everyone, from the very young to elderly. Flavay® has no known contraindications (conditions under which it should not be used). Flavay® is completely safe and nontoxic. In fact, clinical trials have been conducted in which pregnant women (troubled by varicose veins and other circulatory problems in the legs) safely used Flavay®. (3) Safety of Flavay Plus® The essential vitamins and minerals in Flavay Plus® are naturally-derived and completely safe. Flavay Plus® includes phosphatidyl serine, derived from soy lecithin, which has been proven safe in standard toxicology tests. From the large number of human studies conducted, phosphatidyl serine has developed a flawless safety record and proven compatible with a wide array of medications. (26) Consumers need to know that the marketplace is full of imitations, various “extracts” and derivative forms of Dr. Masquelier’s scientifically proven and patented complex. Unfortunately, many have even used Dr. Masquelier’s name and research in unauthorized ways to promote illegitimate products. Flavay is the name you can trust for the precisely defined active polyphenol complex patented and perfected by the inventor, Dr. Jack Masquelier, validated by the French Ministry of Health and documented by a library of research consisting of many patents and hundreds of scientific papers, articles, doctorate theses, lectures and presentations. For quality, consistency, bioavailablity and safety, consumers may rely upon Flavay®. Flavay® and Flavay Plus®
Altogether, this research shows that Flavay® and Flavay Plus® can help people of all ages confront the stressful challenges of living in today's world with improved concentration and attention—providing you and your family with the best that nutritional science has to offer in convenient, cost effective capsules. CLICK HERE TO
SEE WHAT FLAVAY® CUSTOMERS ARE SAYING |
 All About Flavay® | Flavay
Plus® | What Does it Do? |
Proven Safety |
Directions for Use | Q&A Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
|
| REFERENCES: | Top
 |
| 1. Masquelier, J. Plant extract
with a proanthocyanidins content as a therapeutic agent having radical
scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987. 2. Lombard, J., (board certified neurologist), Germano, C. The Brain Wellness Plan - Breakthrough Medical, Nutritional and Immune-Boosting Therapies to Prevent and Treat Depression, Alzheimer's Disease, Chronic Fatigue Syndrome, Attention Deficit Disorder, Multiple Sclerosis, Parkinson's Disease, Lou Gehrig's Disease. Kensington Pub. Corp., 1998. 3. Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega Editrice, Pub., 1996. 4. Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995. 5. Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997. 6. Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century. Warner Books, Inc., 1999. 7. Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985. 8. Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995. 9. Lieberman, S., et al. The real vitamin & mineral book: going beyond the RDA. Avery Pub., 1990. 10. ___. Inadequate intake of vitamins, particularly B-1, can result in mental illness. Clin. Neuro, 8 (Jul.--Sep. 1985):286-293. 11. ___. Carpal tunnel syndrome treated with riboflavin and pyridoxine. Proceedings of the Nat. Acad. of Sc. 81 (Nov. 1984):7076-8. 12. ___. High calorie diets with disproportionately low intakes of vitamins and minerals may be the source of widespread marginal malnutrition. Journ of the Amer Col of Nut, 7 (1988):61-67. 13. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. 14. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. 15. Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981. 16. Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969. 16. Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978. 18. Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977. 19. Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990. 20. Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17. 21. Masquelier, J. Proanthocyanidins et radicaux libres. 1985. 22. Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832. 23. Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504. 24. Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80. 25. Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337. 26. Kidd, P.M. Phosphatidylserine: the nutrient that accelerates all brain functions and counters Alzheimer’s disease: Keats Pub. 1998. 27. O'Brien, C., "Answers to ADD," Vitamin Retailer, March 2002. 28. Cenacchi T, et al. Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging, 5: 123–133, 1993. 29. Maggioni M, Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 81: 265–270, 1990. 30. Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology, 34: 18–21, 1996. 31. Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 43: 385–388, 1992. 32. Cenacchi T, et al., “Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.” Aging, 5, 123-133, 1993 33. Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res, 317:1235-46, 1989. 34. Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, F.A. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. Journal of the Amer Med Assoc, 278 (16):1327-32, 1997. 35. Waagepetersen, H.S., Sonnewald, U., Schousboe, A. The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem, 73:1335–42, 1999. 36. Goddard, A.W., Mason, G.F., Almai, A., Rothman, D.L., Behar, K.L., Petroff, O.A.C., Charney, D.S., Krystal, J.H. Reductions in occipital cortex gaba levels in panic disorder detected with h-magnetic resonance spectroscopy. Arch Gen Psychiatry, 58:556-561, 2001. 37. Braverman, E., et al. The healing nutrients within: in facts, findings and new research. Keats, 1987. 38. Cavagnini, F., et al. Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. Acta Endocrinol, 93:149–54, 1980. 39. Bhagavan, H.N., et al. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics, 1975;55: 437-41. 40. ___. Along with riboflavin, vitamin B-6 deficiency has a primary role in the cause of emotional disorder. British Journal of Psychiatry, 141(1982):271-272. 41. ___. Current data suggest that as many as 20 percent of medically cleared population of outpatient depressives may suffer from a vitamin B-6 deficit. The authors point out that nutrition, diet and vitamin levels have received very little attention in the psychiatric literature. Biological Psychiatry, 9:4 (1984):613-6. 42. ___. Does depressive illness cause vitamin B-6 inadequacy, or vice-versa? Nut Rep Int, 27 (Apr. 1993):867-873. 43. Martineau, J., et al. Vit. B6, magnesium, and combined B6-Mg: therapeutic effects. Bio Psy, 20:467-78, 1985. 44. Dolphin, et al. (eds). Vitamin B6: pyridoxal phosphate. John Wiley & Sons, 1986, chapt. 17. 45. Langseth, L., et al. Glucose tolerance and hyperkinesis. Food and Cosm Toxicology, 16 Aug. 1977. 46. Bekaroglu, M., Aslan, Y., Gedik, Y., Deger, O., et al. Relationships between serum free fatty acids and zinc, and attention deficit disorder: a research note. J. Child Psychol. Psychiatry 1996 Fed; 37 (2):225-7. 47. Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. 48. Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. 49. Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990. 50. Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984. 51. Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985. 52. Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30. 53. Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9. 54. Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15. 55. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40. 56. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40. 57. Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305. 58. Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990. 59. Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981. 60. Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980. 61. Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983. 62. Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981. 63. Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802. 64. Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100. 65. Wegrowski, J., Robert, A.M., Maczar, M. Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497. 66. Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989. 67. Masquelier, J. Pycnogenols: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256. 68. Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106. 69. Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.” pp. 88-93. 70. Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29. 71. Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999. 72. Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980. 73. Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956. Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22. 74. Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude EIVE.’ Unpub., pp. 77-83. 75. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237. 76. Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980. 77. Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73. 78. Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988. 79. Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988. 80. Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988. 81. Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981. 82. Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981. 83. Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988. 84. Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978. 85. Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987. 86. Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981. 87. Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982. 88. Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984. 89. Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981. 90. Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972. 91. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983. 92. Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977. 93. Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61. 94. Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985. 95. Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999. 96. Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports People. 97. Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990. 98. Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International d’Angiologie, Toulouse, France, 4-7 Oct. 1989. 99. Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract submitted to national meeting of the Amer College of Sports Medicine, June 1998. 100. Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm 43: 385–388, 1992. 101. Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Bio of Sport 15(3):135-44, 1998. 102. Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux, 1976. 103. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation de l’acide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304. 104. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306 105. Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. “Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull. 33(11)1985. 5079-5082. 106. Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977. 107. Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235. 108. Masquelier, J., et al. “Flavonoids et Pycnogenols” Int J Vit Nut Res, (49)3:307-311, 1979. 109. Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987. 110. Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971. 111. Laparra, J., et al., Acta Therapeutica, 4:233, 1978. 112. Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects 143010 & 143021; Feb. 1989. 113. Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971. 114. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990. 115. Carper, J., Miracle Cures : Dramatic New Scientific Discoveries Revealing the Healing Powers of Herbs, Vitamins, and Other Natural Remedies, HarperCollins Publishers, 1998. 116. Philpott, W.H., Kalita, D.K., et al., Brain Allergies: The Psychonutrient Connection, Keats Publishing, 1980. 117. Journal of the American Medical Association report on meeting of experts on the subject of food and behavior. Conclusions from this conference were summarized as follows: "Dietary pharmacology is no longer at the fringe of medicine ... Foods do affect behavior. Foods do affect the brain." JAMA 254:4, Dec. 27, 1985. 118. Wender, E.H., Solanto, M.V., "Effects of sugar on aggressive and inattentive behavior in children with attention deficit disorder with hyperactivity and normal children." Pediatrics, 1991 Nov; 88 (5): 960-6. 119. Kaneko, M., et al., "Hypothalamic-putuitary-adrenal axis function in children with attention deficit hyperactivity disorder." 120. The Journal of Autism and Developmental Disorders, 1993 Mar; 23 (1): 59-65. 121. Vatz, R.E., professor at Towson State University, and Weinberg, L.S., of the University of Pittsburg, "Attention Deficit Delirium," Wall Street Journal, July 27, 1994. 122. Physicians Desk Reference® (PDR®), 53rd Edition, Medical Economics Company. 123. Breggin P.R., Director, Int Cntr for the Study of Psychiatry and Psychology; Testimony Before the Subcommittee on Oversight and Investigations Committee on Education and the Workforce U.S. House of Representatives, September 29, 2000. 124. Breggin, P.R., "Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action," International Journal of Risk and Safety in Medicine, 12, 3-35, 1999. 125. Lambert, N., "Stimulant treatment as a risk factor for nicotine use and substance abuse," Program and Abstracts, 191-8, 1998. NIH Consensus Development Conference Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. November 16-18, 1998. William H. Natcher Conference Center. National Institutes of Health. Bethesda, Maryland. 126. American Academy of Pediatrics, "Practice guideline: Diagnosis and evaluation of a child with attention-deficit/hyperactivity disorder," Pediatrics, 105, 1158-70, 2000. 127. Hallowell, E.M., Ratey, J.J., "Driven to Distraction: Recognizing and Coping With Attention Deficit Disorder," Simon & Schuster, 1995. 128. Campbell, L.R., and Cohen, M., "Management of Attention Deficit Hyperactivity Disorder: A Continuing Dilemma for Physicians and Educators," Clinical Pediatrics, March, 1990, 29: 191-3. 129. Balch, J.F., "The Super Antioxidants - Why They Will Change The Face of Healthcare in the 21st Century," M. Evans and Company, Inc., 1998. 130. Passwater, R., Avery Publishing. 131. Weintraub, S., "Natural Treatments for ADD and Hyperactivity," Woodland Publishing, 1997. 132. Diller, L.H., "Running On Ritalin: A Physician Reflects on Children, Society, and Performance in a Pill," Bantam Books, 1998, 42-43. 133. Reichenberg-Ullman, J., Ullman, R., "Ritalin Free Kids: Safe and Effective Homeopathic Medicine for ADD and Other Behaviorial and Learning Problems," Prima Health Publishing, 1996. 134. "Ritalin Finding Its Way Into the Schoolyard," Seattle Times, February 9, 1996; idem. 135. "A Risky Rx for Fun," Newsweek, October 30, 1995, 74; idem. 136. Adesman, A.R., Wender, E.H. "Helping the Hyperactive Child," Patient Care, March 30, 1992, 96-116. 137. Wender, P.H., Attention Deficit Disorder in Adults, New York/Oxford: Oxford University Press, 1995, 166. 138. Swanson, J.M., et al., "Effect of Stimulant Medication on Children with Attention Deficit Disorder: A Review of Reviews," Exceptional Children, 60, 1993: 154-162. 139. Bhagavan, H.N., Coleman, M., Coursin, D.B."The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children." Pediatrics 1975;55: 437-41. 140. Martineau, J., Barthelemy, C., Garreau, B., Lelord, G. "Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism." Biological Psychiatry 1985;20:467-78 141. Dolphin, et al (eds). Vitamin B6: Pyridoxal Phosphate. Toronto: John Wiley & Sons, 1986, chapter 17. 142. The International Nutrition Company Special Report: "Masquelier's Original OPCs and 10 grape seed extracts: An Independent State of the Art Comparative Analysis," November 1997. 143. Vogel, J., "A Stress Test for Children; Is Your 'Problem Child's' Problem Nutrition?", Keats Publishing, 1983. 144. Langseth, L., Dowd, J., "Glucose tolerance and hyperkinesis," Food and Cosmetic Toxicology, 16 August 1977. 145. Monkeberg, F., Schrimshaw, N.S., Gordon, J.E., et al., "Effect of early marasmic malnutrition on subsequent physical and psychological development," Malnutrition, Learning and Behavoir, Cambridge, Mass.: MIT Press, 1968. 146. Crook, W.G.,"Can a What a Child Eats Make Him Dull, Stupid or Hyperactive?", Journal of Learning Disabilities, 13:53-58, 1980. 147. Egger, J., et al., "Controlled Trial of oligoantigenic treatment in the hyperkinetic syndrome, Lancet, 1985 Mar 9: 540-5. 148. Kidd, P., "Phospholipids: life's buildling blocks." Vitamin Retailer, Oct. 2002. 149. Benton, D, et al., Nutr Neurosci 2001;4;169. 150. Kidd, P., Total Health 2002;24: Resource Guide, May-June. |
|
| Top
|
|
.